ClinicalTrials.gg
RecruitingNCT06455332HdeFIMSUpdated Aug 24, 2025

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome

An interventional study of Optic nerve MRI sequence in Clinically Isolated Syndrome and Multiple Sclerosis, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Multiple Sclerosis by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Lille.

Started
2025
with 1 other
No phase
4 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, this one is one of 2 that started in 2025, is one of 4 with no phase, and was the 9th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 11 studies in Multiple Sclerosis by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Multiple Sclerosis by University Hospital, Lille, or all of them as a file.
02

Study summary

Optic neuritis (ON) represents around 30% of clinical presentation of clinically isolated syndrome (CIS). Asymptomatic optic nerve involvement is very frequent in all stage of multiple sclerosis (MS) disease including the CIS. However, optic nerve is still not part of MS diagnosis criteria. The main objective of our regional and multicenter study is to evaluate the prognostic value of optic nerve involvement at the earliest clinical stage of MS (=CIS) for the diagnosis of clinically definite MS (2nd clinical relapse) and the delay until the 2nd relapse.

03

Conditions studied

  • Clinically Isolated Syndrome
  • Multiple Sclerosis

Browse trials for

Keywords

  • Clinically isolated syndrome
  • Multiple sclerosis
  • MRI
  • Optical coherence tomography
  • Optic nerve
  • Diagnostic criteria
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 55 years old
  • Occurrence of CIS ≤ 6 months
  • With two T2 hypersignals on brain/spinal cord MRI suggestive of MS or with oligoclonal bands
  • Giving their written

Exclusion criteria

Exclusion Criteria:

  • Pathological conditions that may skew the optic nerve MRI and/or retinal OCT (diabetes mellitus, glaucoma, retinopathy, ametropia >6 dioptria)
  • Past history of MS relapses
  • Extensive myelitis (>3 vertebral bodies)
  • Bilateral optic neuritis without T2 lesions suggestive of MS
  • to MRI, gadolinium injection
  • Pregnancy, breast-feeding
  • Patients unable to consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    All patients will part of the same follow-up study.

    All patients will part of the same follow-up study. No treatment will be compared. Patients will be treated as recommended.

    Other: Optic nerve MRI sequence

Interventions

  • OtherOptic nerve MRI sequence

    Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal

06

What researchers measure

Primary outcomes

  1. Optic nerve involvement defined by occurrence of a recent clinical episode of ON

    Time frame: assessed at baseline

  2. Asymptomatic optic nerve involvement defined by MRI (detection of an optic nerve T2 hypersignal)

    Time frame: assessed at baseline

  3. Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a second MS clinical relapse

    Time frame: assessed every 6 months during 24 months

  4. Asymptomatic optic nerve involvement defined by OCT (GCIPL-IETD,3pm)

    Time frame: assessed at baseline

  5. Risk of a new clinical relapse will be assessed by the occurrence and time to onset of a CDMS

    Time frame: assessed every 6 months during 24 months

Secondary outcomes

  1. Asymptomatic optic nerve involvement will be defined by: - asymptomatic optic nerve T2 hypersignal detected on one or both optic nerve(s) - or by GCIPL-IETD,3pm measured by OCT - or by GCIPL-IETD≥3µm measured by OCT

    Time to the second clinical relapse occurrence will be assessed every 6 months during 24 months at each neurological examination (M0, M6, M12, M18, M24)

    Time frame: assessed at baseline every 6 months during 24 months

  2. Time to the second clinical relapse occurrence will be assessed every 6 months during 24 months at each neurological examination

    Time frame: assessed at Month 0, Month 6, Month 12, Month 18, Month 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 35 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
Jun 12, 2024
StartActual
Jul 17, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2028
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06455332
Collaborators
Région Nord-Pas de Calais, France, Amiens University Hospital, Boulogne sur Mer Hospital Center, Centre Hospitalier VALENCIENNES, Centre Hospitalier de Roubaix, Centre Hospitalier de Lens
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Jul 17, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Aug 24, 2025

Study contacts

Juliette Bochu
Contact
juliette.bochu@chu-lille.fr
0320444145

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion